Morning salivary dehydroepiandrosterone (DHEA) qualifies as the only neuroendocrine biomarker separating depressed patients with and without prior history of depression: An HPA axis challenge study
- 10 April 2023
- journal article
- research article
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 161, 449-454
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Clinical Patterns and Treatment Outcome in Patients with Melancholic, Atypical and Non-Melancholic DepressionsPLOS ONE, 2012
- Depression and Hypothalamic-Pituitary-Adrenal Activation: A Quantitative Summary of Four Decades of ResearchPsychosomatic Medicine, 2011
- Modulation of the mineralocorticoid receptor as add-on treatment in depression: A randomized, double-blind, placebo-controlled proof-of-concept studyJournal of Psychiatric Research, 2010
- Cognitive, physiological, and personality correlates of recurrence of depressionJournal of Affective Disorders, 2005
- The Number of Previous Depressive Episodes Is Positively Associated with Cortisol Response to Fenfluramine AdministrationAnnals of the New York Academy of Sciences, 2004
- Elevation of the Cortisol-Dehydroepiandrosterone Ratio in Drug-Free Depressed PatientsAmerican Journal of Psychiatry, 2002
- Dehydroepiandrosterone (DHEA) treatment of depressionBiological Psychiatry, 1997
- Adrenal secretion during major depression in 8- to 16-year-olds, I. Altered diurnal rhythms in salivary cortisol and dehydroepiandrosterone (DHEA) at presentationPsychological Medicine, 1996
- The overnight single‐dose metyrapone test is a simple and reliable index of the hypothalamic‐pituitary‐adrenal axisClinical Endocrinology, 1994
- Multiple depressive episodes and plasma postdexamethasone cortisol levelsBiological Psychiatry, 1987